Ganciclovir for injection

Nucleoside antiviral drugs. After entering the cell, this product is rapidly phosphorylated into a monophosphate compound, and then becomes a triphosphate compound through the action of cellular kinase. Its phosphorylation is faster in cells infected with cytomegalovirus than in normal cells. Ganciclovir can competitively inhibit DNA polymerase and incorporate into the DNA of viruses and host cells, thereby inhibiting DNA synthesis. This product has a stronger inhibitory effect on viral DNA polymerase than on host cell polymerase. In animal experiments, this product has teratogenic, carcinogenic, immunosuppressive effects and reproductive system toxicity.

Ganciclovir.

This product is white loose mass or powder; it is hygroscopic.

1. Used to treat cytomegalovirus hepatitis. 2. Used for immunodeficient patients with cytomegalovirus infection. 3. Used to prevent cytomegalovirus infection in patients receiving organ transplants. 4. Used to treat severe infections caused by herpes virus.

1 Induction phase: intravenous drip of 5 mg/kg per body weight, once every 12 hours, each drip for more than 1 hour, the course of treatment is 14 to 21 days, and the dose should be reduced for patients with renal impairment. When the creatinine clearance rate is 50-69 ml/min, intravenous drip of 2.5 mg/kg every 12 hours; when the creatinine clearance rate is 25-49 ml/min, intravenous drip of 2.5 mg/kg every 24 hours; when the creatinine clearance rate is 10-24 ml/min, intravenous drip of 1.25 mg/kg every 24 hours; when the creatinine clearance rate is <10 ml/min, the drug is given 3 times a week, each time 1.25 mg/kg is given after hemodialysis. 2 Maintenance phase: intravenous drip of 5 mg/kg per body weight, once a day, intravenous drip for more than 1 hour.

1. Common adverse reactions include bone marrow suppression. After taking the drug, about 40% of patients have a neutrophil count reduced to less than 1000/mm3, and about 20% of patients have a platelet count reduced to less than 50,000/mm3. In addition, anemia may occur. 2. Central nervous system symptoms such as mental abnormalities, tension, tremors, etc., with an incidence of about 5%, and occasionally coma, convulsions, etc. 3. Rash, itching, drug fever, headache, dizziness, dyspnea, nausea, vomiting, abdominal pain, loss of appetite, abnormal liver function, gastrointestinal bleeding, arrhythmia, increased or decreased blood pressure, hematuria, increased blood urea nitrogen, hair loss, decreased blood sugar, edema, general discomfort, increased creatinine, eosinophilia, local pain at injection, phlebitis, etc. AIDS patients with cytomegalovirus retinitis may experience retinal detachment.

It is contraindicated for patients who are allergic to this product or acyclovir.

1. When used with drugs that affect the hematopoietic system, bone marrow suppressants and radiotherapy, the inhibitory effect on the bone marrow can be enhanced. 2. When used with nephrotoxic drugs (such as amphotericin B, cyclosporine), this product may enhance renal damage, reduce the renal excretion of this product and cause toxic reactions. 3. When used with zidovudine, it can enhance the toxicity to the hematopoietic system and must be used with caution. 4. When used with didanosine or used successively, the area under the drug-time curve of the latter can be significantly increased (increased by 72% to 111%), and the renal clearance of the two remains unchanged. 5. When used with imipenem-cilastatin, systemic convulsions may occur. 6. When used with probenecid or drugs that inhibit renal tubular secretion, the renal clearance of this product can be reduced by about 22%, and its area under the drug-time curve can be increased by about 53%, which is prone to toxic reactions. 7. Avoid using it with dapsone, pentamidine, flucytosine, vinblastine, doxorubicin, trimethoprim, sulfonamides and nucleoside drugs.

Sealed, store in a dry place.

250mg

Changchun HaiYue Pharmaceutical Limited By Share Ltd.

• Founded in:

  1992-09-12

• Address:

  No. 5555, Shuangying Road, Shuangyang Economic Development Zone, Shuangyang District, Changchun City

• Tax NO.:

  912201016059030427

• Registered Funds:

  226.1666 million yuan

• Email:

  Log in to view